Spinal Inflammation: Causes, Symptoms, and Treatments

Spinal inflammation is not a single disease but a common thread running through a wide range of conditions, from autoimmune disorders like ankylosing spondylitis to bacterial infections of the vertebrae. The underlying causes determine how the inflammation behaves, what damage it can do, and how it should be treated. What ties these conditions together is that the immune system’s inflammatory response targets structures in or around the spine, whether that means the joints between vertebrae, the bone marrow inside them, or the membranes surrounding the spinal cord itself.

Why the Spine Is Vulnerable to Inflammation

The spine is a complex stack of bones, discs, ligaments, and tendons, and the points where those structures meet are especially prone to immune activity. In spondyloarthritis, a group of inflammatory diseases that includes ankylosing spondylitis, inflammation tends to start at entheses, the spots where tendons and ligaments attach to bone. These areas are rich in immune cells and sit at mechanical stress points, making them natural flashpoints. Genetic and clinical evidence points to specific immune signaling molecules, particularly interleukin-17 and interleukin-23, as key drivers of disease in this family of conditions.¹

Recent research has shown that two forms of IL-17 (IL-17A and IL-17F) work together with another inflammatory molecule, TNF, to ramp up the inflammatory response in spinal tissues. When these signals combine, they trigger a cascade of chemokines and pro-inflammatory mediators in the stromal cells around entheses, amplifying the damage well beyond what any single signal would cause.² The genetic side reinforces this picture: people with ankylosing spondylitis carry polymorphisms in genes governing the TNF, IL-23/IL-17, and NF-κB pathways at higher rates than the general population.³

Autoimmune and Immune-Mediated Causes

Ankylosing spondylitis is the best-known autoimmune driver of spinal inflammation. It typically begins in young adults, often before age 45, and progressively fuses the vertebrae if left untreated. The gene HLA-B27 has long been linked to the disease, contributing roughly a fifth of its heritability.⁴ But carrying HLA-B27 is neither necessary nor sufficient to develop the condition. Most people who test positive for the gene never get ankylosing spondylitis, which means other genetic and environmental factors are clearly in play.

Spondyloarthritis as a broader category also includes psoriatic arthritis, reactive arthritis, and arthritis linked to inflammatory bowel disease. All of these can involve spinal inflammation, though the pattern and severity differ. What they share is a tendency to inflame the axial skeleton, peripheral joints, and entheses, and, over time, to cause structural damage including new bone growth that can bridge vertebrae together.¹

A separate but important immune-mediated cause is neuromyelitis optica spectrum disorder, a rare autoimmune condition that inflames the optic nerves and the spinal cord itself. This produces transverse myelitis, inflammation that cuts across the spinal cord and can cause weakness, numbness, and loss of bladder or bowel control. The mechanism is different from spondyloarthritis: the immune system attacks aquaporin-4, a water channel protein on spinal cord cells, rather than targeting joints and entheses.⁵

Infection as a Cause

Not all spinal inflammation is autoimmune. Vertebral osteomyelitis, infection of the spinal bones, is a serious and sometimes underdiagnosed condition. The most common culprit is Staphylococcus aureus, though gram-negative bacteria, fungi, and even parasites can cause it.⁶ Bacteria typically reach the spine through the bloodstream, often originating from a urinary tract infection, a skin wound, or an infected heart valve. Spinal surgery and injections also create direct entry points.

The presentation can be tricky. Vertebral osteomyelitis often builds slowly, with worsening back pain over weeks or months, sometimes accompanied by fever but not always. Because the symptoms overlap with common back pain, delays in diagnosis are frequent. Blood tests play a key role in raising suspicion. In chronic spinal infections, the erythrocyte sedimentation rate (a measure of how fast red blood cells settle in a test tube, which rises with inflammation) tends to be more diagnostically useful than C-reactive protein, though clinicians typically order both.⁷

Treatment for bacterial vertebral osteomyelitis typically requires about six weeks of antibiotic therapy, either intravenously or with highly absorbable oral antibiotics. Infections caused by Brucella species, which are acquired through unpasteurized dairy or animal contact, call for a longer course of around three months.⁸

When Disc Degeneration Triggers Inflammation

There is a middle ground between autoimmune disease and infection that catches many people off guard. Modic changes are areas of inflammatory and fibrotic bone marrow damage visible on MRI, and they sit right next to degenerating discs. They are surprisingly common in people with chronic low back pain. The leading theory is that when a disc deteriorates and its end plate cracks, material from the disc’s nucleus leaks into the adjacent bone marrow and triggers an immune reaction, essentially an autoimmune response to your own disc tissue.⁹ There is also evidence that bacteria can colonize herniated disc material and fuel the inflammatory process, blurring the line between sterile inflammation and low-grade infection.¹⁰

Modic changes matter because they represent a type of spinal inflammation that does not fit neatly into the “autoimmune” or “infectious” boxes. They may help explain why some people with disc problems have persistent inflammatory pain even when imaging shows only degenerative disease. The research here is still evolving, but it is increasingly clear that the spine’s inflammatory story extends beyond classic rheumatic diseases.

Recognizing Inflammatory Back Pain

The most practically useful thing to understand about spinal inflammation is how its pain differs from ordinary mechanical back pain. The distinction matters because the treatment paths diverge sharply. Inflammatory back pain has a recognizable pattern:

Onset before 45: most inflammatory spinal diseases begin in young adulthood.
Gradual start: the pain builds over months, not from a sudden injury.
Morning stiffness lasting over 30 minutes: this is one of the strongest indicators.
Improvement with movement: pain eases with exercise and worsens with prolonged rest.
Good response to NSAIDs: anti-inflammatory drugs provide noticeable relief.
Night pain: pain that wakes you, particularly in the second half of the night, is common.

These features were identified across multiple clinical criteria sets and consistently appear in diagnostic guidelines.¹¹ Morning pain on waking, in particular, showed high agreement among clinicians as a reliable marker of inflammatory low back pain, while constant pain and stiffness after resting were rated as moderate indicators.¹²

Mechanical back pain, by contrast, tends to worsen with activity and ease with rest. It often follows a specific event, like lifting something heavy. The trouble is that many people have features of both, and primary care physicians sometimes miss inflammatory back pain because it looks, on the surface, like garden-variety low back trouble. When back pain that matches the inflammatory pattern persists for three or more months, it warrants evaluation by a rheumatologist.

How Spinal Inflammation Is Diagnosed

MRI is the workhorse of diagnosis. It can detect bone marrow edema (fluid buildup from inflammation) in the sacroiliac joints and vertebrae well before structural damage becomes visible on X-ray. In axial spondyloarthritis, active inflammatory lesions show up as bright areas on a particular MRI sequence called STIR, which is sensitive to water content in tissues.¹³ This is a major advance over earlier decades, when the only way to confirm ankylosing spondylitis was to wait for visible fusion on plain X-rays, often years into the disease.

Blood tests complement imaging. For suspected infection, ESR and CRP are standard; in chronic spinal infections, an ESR above roughly 20 to 30 mm/h tends to be more useful than CRP alone for flagging the problem.⁷ For autoimmune conditions, HLA-B27 testing can be helpful as part of a broader diagnostic picture, though a positive result alone does not confirm disease. CRP is also used to track disease activity in spondyloarthritis over time, which feeds into treatment decisions.

Drug Treatments for Autoimmune Spinal Inflammation

NSAIDs remain the first line for inflammatory back pain in spondyloarthritis. They are genuinely effective here, unlike their more modest role in mechanical back pain. A trial comparing epidural steroid injections to NSAIDs for low back pain with radiating leg pain found that both approaches produced significant improvement.¹⁴ For many patients with mild to moderate disease, continuous NSAID use is enough to control symptoms.

When NSAIDs are not sufficient, biologic therapies targeting specific immune pathways have transformed outcomes. TNF inhibitors like adalimumab, infliximab, and etanercept were the first biologics approved for ankylosing spondylitis and remain widely used. More recently, drugs targeting IL-17 (secukinumab, ixekizumab, bimekizumab) have become available, along with JAK inhibitors like tofacitinib and upadacitinib.¹⁵ These medications produce meaningful remission in many patients, though they carry risks including increased susceptibility to infections.

The question of whether combining biologics could work even better than single agents is being explored. In an animal model of spondyloarthritis, blocking both TNF and IL-17A simultaneously reduced spinal inflammation and pannus formation (the aggressive tissue that erodes joints), though the dual therapy did not dramatically outperform either drug alone.¹⁶ The newer biologic bimekizumab already combines IL-17A and IL-17F blockade in a single molecule, which represents a step in this direction in humans.

Exercise and Physical Therapy

Exercise is not just helpful for inflammatory spinal conditions; it is considered a core part of treatment. This sometimes surprises people, because the instinct when your spine hurts is to rest. But in autoimmune spinal inflammation, rest is precisely what makes things worse. Regular exercise is recommended as an essential management strategy for axial spondyloarthritis, with programs tailored to individual symptoms, functional goals, and comorbidities.¹⁷

The evidence backs this up concretely. A six-month intensive exercise program for patients with axial spondyloarthritis led to measurable improvements in disease activity scores and spinal mobility, and also reduced serum calprotectin, a blood marker of inflammation.¹⁸ Even a shorter two-week daily physical therapy program produced clinically relevant improvements in spinal function and mobility.¹⁹ The key is consistency: brief spurts of exercise do not appear to sustain benefits the way ongoing programs do.

The Gut Connection

One of the more surprising developments in spinal inflammation research is the growing evidence that the gut plays a significant role. The “gut-bone axis” refers to the relationship between gut bacteria, mucosal immune activity, and skeletal inflammation. People with ankylosing spondylitis frequently have abnormal gut microbiomes, and a substantial proportion show subclinical gut inflammation even without bowel symptoms.²⁰ The overlap with inflammatory bowel disease is not coincidental: the two conditions share genetic risk factors, immune pathways, and sometimes co-occur in the same person.

Dietary interventions are being explored, though the evidence remains thin. A systematic review of nutrition in axial spondyloarthritis found limited but promising data on polyunsaturated fatty acid supplements (such as omega-3s), and noted that synbiotics, which combine probiotics with prebiotics, showed some ability to reduce IL-17, the very cytokine most implicated in spondyloarthritis.²¹ Vitamin D supplementation and pomegranate extract also showed anti-inflammatory properties across inflammatory arthritis conditions, though none of these are close to replacing conventional therapy.

When Spinal Inflammation Starts in Childhood

Spinal inflammation does not wait for adulthood. Juvenile spondyloarthritis can begin in children and teenagers, though it tends to look different from the adult version. In young people, the disease predominantly affects peripheral joints, particularly hips, knees, and ankles, while axial involvement (the spine and sacroiliac joints) becomes more common with age.²² Enthesitis, pain and swelling where tendons attach to bone, is often an early and prominent feature in children.

A comparative study found peripheral arthritis in over half of juvenile-onset patients compared to about a fifth of adult-onset patients, while sacroiliitis, axial involvement, and morning stiffness were all significantly more common in adults.²³ This difference in presentation means that a child with enthesitis and a swollen knee might not immediately be evaluated for a condition that will eventually involve the spine. Pediatric rheumatologists are alert to this, but general practitioners and parents may not realize that joint inflammation in a teenager can be the opening chapter of an axial disease.

How Spinal Inflammation Rewires Pain Processing

One of the more frustrating aspects of chronic spinal inflammation is that pain can persist even after the underlying disease is brought under control with biologics. The reason is central sensitization: prolonged inflammation changes how the nervous system processes pain signals. Glial cells in the spinal cord and brain become activated and release their own inflammatory molecules, which amplify pain signals and lower the threshold for what the nervous system treats as painful.²⁴

In spondyloarthritis patients on biologic treatment, this phenomenon can explain why some people report persistent widespread pain despite blood tests and MRI showing that their inflammatory disease is well controlled. The normal balance between excitatory and inhibitory signals in the central nervous system has been disrupted, leading to heightened sensitivity. Pain may spread beyond the original site and become triggered by stimuli that would not normally be painful, like light pressure on the skin.²⁵ Recognizing this pattern matters, because the treatment for centralized pain involves different strategies, including pain neuroscience education, graded exercise, and sometimes medications targeting the nervous system rather than the immune system. Escalating biologic therapy for pain that is actually driven by central sensitization will not help and may expose the patient to unnecessary side-effect risk.

Spinal Inflammation in the Archaeological Record

Ankylosing spondylitis is not a modern disease. Skeletal evidence of spinal fusion consistent with the condition has been found in pre-Columbian remains from Mesoamerica. One specimen, a man from the Postclassic period (roughly 900 to 1521 AD), showed fusion of the vertebral column from the mid-thoracic to the lower lumbar spine, with ossification of the ligaments between the spinal processes, a pattern characteristic of advanced ankylosing spondylitis.²⁶ This finding matters because it establishes that the disease existed in the Americas independently of European contact, confirming that the genetic and immunological factors underlying spinal inflammation have deep roots in human populations across the world. Whatever environmental triggers contribute to these conditions, they are not exclusively products of industrial or post-industrial life.

1
PubMed. Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers
2
PubMed Central. Human spinal enthesis comparative biology of IL-17F and IL-17A reveals greater T-cell IL-17F induction and IL-23 regulation
3
PubMed Central. Polymorphisms in genes regulating inflammation are associated with ankylosing spondylitis
4
PubMed Central. Role of HLA-B27 in the pathogenesis of ankylosing spondylitis
5
PubMed Central. Atypical Neuromyelitis Optica Spectrum Disorder: A Case of Unilateral Optic Neuritis and Partial Transverse Myelitis
6
PubMed. Current knowledge of vertebral osteomyelitis: a review
7
The Open Infectious Diseases Journal. Erythrocyte Sedimentation Rate, C-Reactive Protein and Procalcitonin in Infections of the Spine and Infections in Spinal Cord Injury Patients
8
Clinical Infectious Diseases. IDSA 2015 Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults
9
The Spine Journal. ISSLS Prize in Basic Science 2017: Intervertebral disc/bone marrow cross-talk with Modic changes
10
PubMed Central. Does nuclear tissue infected with bacteria following disc herniations lead to Modic changes in the adjacent vertebrae?
11
PubMed Central. Awareness and knowledge of the common features of inflammatory back pain among primary care physicians in the western region of Saudi Arabia
12
PubMed. Mechanical or inflammatory low back pain. What are the potential signs and symptoms?
13
European Spine Journal. A deep neural network for MRI spinal inflammation in axial spondyloarthritis
14
PubMed. Caudal epidural injection versus non-steroidal anti-inflammatory drugs in the treatment of low back pain accompanied with radicular pain
15
PubMed. Recent advances in biologic therapies for ankylosing spondylitis: A 2024 update
16
PubMed Central. Dual Blockade of TNF and IL-17A Inhibits Inflammation and Structural Damage in a Rat Model of Spondyloarthritis
17
Quality in Sport. Physical Therapy in the Management of Axial Spondyloarthritis: A Narrative Review
18
PubMed Central. Clinical improvement and reduction in serum calprotectin levels after an intensive exercise programme for patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis
19
PubMed Central. Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis
20
PubMed Central. The gut-bone axis in ankylosing spondylitis: mechanistic insights and the translational gap
21
PubMed Central. Nutrition and diet in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: a systematic review
22
PubMed Central. Similarities and Differences Between Juvenile and Adult Spondyloarthropathies
23
PubMed Central. Juvenile vs. Adult-Onset Spondyloarthritis: Uncovering Similarities and Differences
24
PubMed Central. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain
25
PubMed Central. Central Sensitization and Its Role in Persistent Pain Among Spondyloarthritis Patients on Biological Treatments
26
PubMed. Ankylosing spondylitis is indigenous to Mesoamerica